Moorestown, NJ, September 07, 2016 –(PR.com)– Tabula Rasa HealthCare, Inc.’s (TRHC) Chief Strategy Officer, Brian J. Litten, Esq., is scheduled to present a “Stakeholder Perspective” onEnhanced Medication Therapy Management (EMTM) at the Second Annual Medication Therapy Management & Outcomes Summit (MTM Summit). The conference will be held September 15-16, 2016, at the Pier 5 Hotel in Baltimore, MD.
Since the Medicare Part D prescription drug benefit was created by the Medicare Modernization Act of 2003, the concept of Medication Therapy Management (MTM) was mandated to optimize medication therapies, improve outcomes and reduce costs. Stakeholders agree, however, traditional MTM has fallen short of its goals, particularly with standalone Prescription Drug Plans (PDPs), which lack appropriate information and incentives to fuel a meaningful impact on medical quality and costs. Recognizing this, the Centers for Medicare and Medicaid Innovation (CMMI) has designed EMTM to re-align incentives and foster innovation around MTM.
TRHC presented at the First Annual MTM Summit in 2015, just after CMMI announced the CMMI EMTM model. Since then, much more information has been learned and much more work has been undertaken to improve the effectiveness of MTM under the EMTM Model.
TRHC is a leader in MTM innovations. TRHC’s Medication Risk Mitigation Matrix® brings to EMTM the ability to identify those Medicare beneficiaries at the highest risk of an adverse drug event – resulting in more than 100,000 deaths annually – and mitigates that risk through personalized interventions. TRHC will use its Medication Risk Mitigation Matrix and certain other services to perform medication risk stratification and reviews and safety assessments of complex medication regimens, providing an innovative, alternative approach to pharmacotherapy.
At this year’s MTM Summit, THRC will focus on the EMTM Model, and the work TRHC has done to support eligible standalone PDPs in participating in the five-year program.